{"prompt": "['Trial ID: LP0162-1325', 'Date: 14-Aug-2018', 'Version: 4.0', 'Page 120 of 169', 'Methodology', 'Trial design', '(continued)', 'Subjects found eligible following the screening period will be randomised 3:1', 'to tralokinumab 300 mg Q2W or placebo. Randomisation will be stratified by', 'region and disease severity.', \"Subjects achieving a clinical response at Week 16 (defined as Investigator's\", 'Global Assessment [IGA] of 0 or 1 on a 5-point scale ranging from 0 [clear] to', '4 [severe], or at least 75% reduction in Eczema Area and Severity Index', '[EASI] score from baseline [EASI75]) will continue into maintenance', 'treatment that will continue until Week 52.', 'Subjects randomised to tralokinumab in the initial treatment period will be', 're-randomised 2:2:1 to one of the following Q2W maintenance regimens', 'stratified by region and IGA response at Week 16 (IGA 0/1 or IGA >1):', 'Tralokinumab 300 mg Q2W.', 'Alternating dose administrations tralokinumab 300 mg and placebo', \"('tralokinumab Q4W')\", 'Placebo.', 'Subjects randomised to placebo in the initial treatment period who achieve a', 'clinical response at Week 16 (defined by IGA of 0 or 1, or EASI75) will', 'continue to receive placebo Q2W in the maintenance treatment period.', 'Subjects not achieving a clinical response at Week 16 as well as those who', 'meet the criteria listed below during maintenance treatment will be transferred', 'to open-label tralokinumab 300 mg Q2W treatment with optional use of TCS', 'up to Week 52.', 'Transfer to open-label treatment', 'Subjects with IGA=0 at Week 16: IGA of at least 2 and not achieving EASI75', 'over at least a 4-week period (i.e., over 3 consecutive visits).', 'Subjects with IGA=1 at Week 16: IGA of at least 3 and not achieving EASI75', 'over at least a 4-week period (i.e., over 3 consecutive visits).', 'Subjects with IGA>1 at Week 16: not achieving EASI75 over at least a 4-week', 'period (i.e., over 3 consecutive visits).', 'For selected countries', 'Subjects transferring to open-label treatment will have the option to', 'self-administer tralokinumab in their home after adequate training (at 3 dosing', 'visits in the open-label period after additional consent has been obtained) by', \"site staff at the investigator's discretion.\", 'For selected countries', 'Subjects who join the open-label tralokinumab arm at Week 16 will continue an', 'additional 16 weeks of open-label treatment in order to secure at least 52 weeks', 'of active therapy (Week 52 to Week 68).', 'Number of subjects', 'A total of 780 subjects will be randomised 3:1 to initial treatment (585 subjects', 'to be enrolled', 'to tralokinumab; 195 subjects to placebo).', 'eDoc-00631888 - Version 4.0']['Trial ID: LP0162-1325', 'Date: 14-Aug-2018', 'Version: 4.0', 'Page 121 of 169', 'Main criteria for', 'Age 18 and above.', 'inclusion', 'Diagnosis of AD as defined by the Hanifin and Rajka (1980) criteria', 'for AD.', 'Diagnosis of AD for >1 year.', 'Subjects who have a recent history of inadequate response to treatment', 'with topical medications or for whom topical treatments are otherwise', 'medically inadvisable.', 'AD involvement of 10% body surface area at screening and baseline.', 'An EASI score of >12 at screening and 16 at baseline.', 'An IGA score of >3 at screening and at baseline.', 'A Worst Daily Pruritus numeric rating scale (NRS) average score of >4', 'during the week prior to baseline.', 'Stable dose of emollient twice daily (or more, as needed) for at least', '14 days before randomisation.', 'Main criteria for', 'Active dermatologic conditions that may confound the diagnosis of', 'exclusion', 'AD.', 'Use of tanning beds or phototherapy within 6 weeks prior to', 'randomisation.', 'Treatment with systemic immunosuppressive/immunomodulating', 'drugs and/or systemic corticosteroid within 4 weeks prior to', 'randomisation.', 'Treatment with TCS and/or TCI within 2 weeks prior to randomisation.', 'Active skin infection within 1 week prior to randomisation.', 'Clinically significant infection within 4 weeks prior to randomisation.', 'A helminth parasitic infection within 6 months prior to the date', 'informed consent is obtained.', 'Tuberculosis requiring treatment within the 12 months prior to', 'screening.', 'Known primary immunodeficiency disorder.', 'Investigational', 'Tralokinumab', 'medicinal products', '150 mg/mL solution for subcutaneous (SC) injection in an accessorised', 'pre-filled syringe, 1.0 mL fill volume. Each kit contains 1 syringe.', 'Placebo', 'Placebo solution for SC injection in an accessorised pre-filled syringe, 1.0 mL', 'fill volume. Each kit contains 1 syringe.', 'Duration of', 'Screening period (including wash-out, if applicable) up to 6 weeks, treatment', 'treatment', 'period of 52 weeks (or 68 weeks in selected countries), follow-up period of', '14 weeks (subjects may enter the long-term extension trial [LP0162-1337,', 'ECZTEND], at any time during the safety follow-up period).', 'eDoc-00631888 - Version 4.0']\n\n###\n\n", "completion": "END"}